Clinical Trials Logo
  1. Home
  2. Metastatic Prostate Cancer
  3. NCT00213694
  4. Details
NCT00213694 Clinical Trial

PROSTACOX : Metastatic Prostate Chemotherapy

Metastatic Prostate Cancer Clinical Trial

Official title:
Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00213694
Other study ID # 2003/052/HP
Secondary ID
Status Completed
Phase Phase 2
First received September 13, 2005
Last updated March 4, 2013
Start date November 2003
Est. completion date June 2006

Study information
Verified date March 2013
Source University Hospital, Rouen
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Observational

Clinical Trial Summary

Clinical response to chemotherapy. Biological parameter (PSA) and RECIST evaluation. Association of Docetaxel (J 15) and Celecoxib.

Description:

Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA Clinical status RECIST evaluation

Recruitment information / eligibility
Status Completed
Enrollment 52
Est. completion date June 2006
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- metastatic prostate cancer

- ASCO progression criteria

Exclusion Criteria:

- other prostate chemotherapy

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Intervention

Drug:
• docetaxel and celecoxib

Locations
Country Name City State
France Charles Nicolle, University Hospital Rouen

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Recruiting NCT04533958 - Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy N/A
Not yet recruiting NCT06009549 - A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
Withdrawn NCT05771896 - Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC Phase 3
Completed NCT01981122 - A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Phase 2
Completed NCT01233557 - Biomarkers of Bone Resorption in Metastatic Prostate Cancer N/A
Completed NCT01012141 - Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer Phase 2
Recruiting NCT04067713 - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
Active, not recruiting NCT04332744 - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) Phase 2
Completed NCT04545697 - mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer N/A
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Completed NCT02278055 - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT04193657 - Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Completed NCT02260817 - Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer Phase 3
Terminated NCT00216060 - Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy Phase 3
Recruiting NCT04070209 - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Phase 2
Recruiting NCT04925648 - Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction Phase 2
Completed NCT01303705 - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Phase 1